Defining the quality of interdisciplinary care for patients with brain metastases: modified Delphi panel recommendations.

Autor:	Fadul CE; Department of Neurology, Division of Neuro-Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA. Electronic address: cef3w@uvahealth.org., Sheehan JP; Department of Neurological Surgery, University of Virginia School of Medicine, Charlottesville, VA, USA., Silvestre J; Department of Palliative Care, Loma Linda University School of Medicine, Loma Linda, CA, USA., Bonilla G; University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA., Bovi JA; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Ahluwalia M; Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA., Soffietti R; Department of Neuroscience, Division of Neuro-Oncology, University of Turin and City of Health and Science University Hospital, Turin, Italy., Hui D; Department of Palliative Care, Rehabilitation and Integrative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Anderson RT; University of Virginia Comprehensive Cancer Center, Charlottesville, VA, USA; Department of Public Health, University of Virginia School of Medicine, Charlottesville, VA, USA.
Jazyk:	angličtina
Zdroj:	The Lancet. Oncology [Lancet Oncol] 2024 Sep; Vol. 25 (9), pp. e432-e440.
DOI:	10.1016/S1470-2045(24)00198-0
Abstrakt:	The value of interdisciplinary teams in improving outcomes and quality of care of patients with brain metastases remains uncertain, partly due to the lack of consensus on key indicators to evaluate interprofessional care. We aimed to obtain expert consensus across disciplines on indicators that evaluate the quality and value of brain metastases care. A steering committee of key opinion leaders curated relevant outcomes and process indicators from a literature review and a stakeholder needs assessment, and an international panel of physicians rated the outcomes and process indicators using a modified Delphi method. After three rounds, a consensus was reached on 29 indicators encompassing brain-directed oncological treatment, surgery, whole-brain radiotherapy, stereotactic radiosurgery, supportive or palliative care, and interdisciplinary team care. The Brain Metastases Quality-of-Care measure reflects the value and quality of brain metastases team-based care according to treatment modality and provides a benchmark of care for this under-studied patient population. The adoption, implementation, and sustainability of this set of indicators could help address the need expressed by patients with cancer, caregivers, and clinicians for more coordinated care across inpatient, outpatient, home, community, and tertiary academic settings. Competing Interests: Declaration of interests JPS is on the American Association of Neurological Surgeons’ board of directors. MA is a consultant for Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Varian Medical Systems, Carin Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem therapeutics, and GT Medical Technologies; has received research grants from Seagen; serves on the scientific advisory board for Cairn Therapeutics, Pyramid Biosciences, Modifi Biosciences, and Bugworks; and is a shareholder in Mimivax, Cytodyn, MedInnovate Advisors, and Trisalus Lifesciences. JAB is a consultant for Imaging Biometrics. All other authors declare no competing interests. (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu